Erythromycinum
What is Erythromycinum TZF and what is it used for
Important information before taking Erythromycinum TZF
How to take Erythromycinum TZF
Possible side effects
How to store Erythromycinum TZF
Contents of the pack and other information
Erythromycinum TZF contains the active substance erythromycin. It is a macrolide antibiotic that inhibits the growth of bacteria that cause infections.
Erythromycinum TZF is indicated for the treatment of infections caused by erythromycin-sensitive microorganisms.
If the patient has any of the following conditions, they should inform their doctor before taking the medicine:
If the patient experiences any of the following symptoms while taking Erythromycinum TZF, they should inform their doctor:
During long-term erythromycin treatment, the doctor usually orders liver function tests.
For pregnant women, erythromycin does not penetrate the fetus in therapeutic concentrations. If a pregnant patient with syphilis receives oral erythromycin, the newborn will receive penicillin.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take, including those without a prescription.
lovastatin, simvastatin (medicines used in hypercholesterolemia and coronary artery disease),
rifabutin (an antibiotic used in the treatment of tuberculosis),
digoxin, quinidine, disopyramide, procainamide (medicines used in the treatment of heart rhythm disturbances),
alfentanil, triazolam, midazolam (medicines used in anxiety or insomnia),
anticoagulant medicines, e.g. warfarin, acenocoumarol, and rivaroxaban (used to thin the blood),
carbamazepine, valproic acid, phenytoin (antiepileptic medicines),
methylprednisolone (an anti-inflammatory medicine),
cyclosporine, tacrolimus (medicines used, among other things, after transplants),
theophylline (a medicine used in the treatment of asthma),
benzodiazepines (medicines used, for example, in insomnia, epilepsy),
oral contraceptives,
colchicine (a medicine used in the treatment of gout),
mizolastine (a medicine used mainly in skin allergic reactions),
bromocriptine (a medicine used, for example, in Parkinson's disease),
hexobarbital (a medicine used as an anesthetic for short operations),
zopiclone (a medicine used in the treatment of insomnia),
corticosteroids, administered orally, by injection, or inhaled (used to weaken the body's immune system - which is useful in the treatment of many diseases),
hydroxychloroquine or chloroquine (used in the treatment of diseases such as rheumatoid arthritis or in the treatment or prevention of malaria). Taking these medicines with erythromycin may increase the risk of abnormal heart rhythm and other serious heart-related side effects.
Effect on Laboratory Test Results
Erythromycin may change the results of urinary catecholamine tests performed using the fluorometric method.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor before taking this medicine.
The active substance of Erythromycinum TZF may pass through the placenta in pregnant women and is excreted in breast milk. Information from studies on the risk of congenital malformations is inconsistent, but in some studies, heart defects were found after taking Erythromycinum TZF in early pregnancy.
Erythromycin can be given to pregnant or breastfeeding women only if, in the doctor's opinion, it is absolutely necessary.
There are no data on the effect of the medicine on the ability to drive and use machines.
Erythromycinum TZF contains less than 1 mmol (23 mg) of sodium per tablet, which means the medicine is considered "sodium-free".
Erythromycinum TZF should always be taken as directed by the doctor. In case of doubts, the patient should contact their doctor or pharmacist.
Usually, 1 g to 2 g per day is administered, in divided doses. In severe infections, the doctor may increase the dose to 4 g per day, administered in divided doses.
Usually, 30 to 50 mg/kg body weight per day is administered, in divided doses every 12 or 6 hours. In severe infections, the doctor may recommend a dose twice as high, administered every 6 hours.
Erythromycinum TZF in tablets can be given to children of any age, provided they are able to swallow the tablet.
In elderly patients, dose adjustment is not necessary. However, due to frequent disorders related to liver or biliary tract dysfunction, caution is recommended in this group of patients.
The duration of treatment depends on the severity and type of infection.
The doctor will determine the appropriate duration of treatment, which should be followed.
Tablets can be taken before or with a meal, with a small amount of boiled, cooled water.
In the treatment of severe and life-threatening infections, the doctor will administer erythromycin intravenously.
Taking a higher dose of Erythromycinum TZF than recommended by the doctor may cause gastrointestinal symptoms (nausea, vomiting, diarrhea) or hearing disturbances.
In case of taking a higher dose of Erythromycinum TZF than recommended, the patient should immediately contact their doctor or go to the nearest emergency department in a hospital. The patient should bring the medicine in its original packaging so that the medical staff can accurately check which medicine was used.
In case of missing a dose of Erythromycinum TZF, the patient should take it as soon as possible, and then take the next dose at the scheduled time.
The patient should not take a double dose to make up for the missed dose.
It is important to take the medicine as directed for the recommended treatment cycle. The patient should not stop treatment because they feel better. If the treatment cycle is stopped too early, the infection may return.
If the patient feels worse during treatment or does not feel well after completing the recommended treatment cycle, they should consult their doctor.
Like all medicines, Erythromycinum TZF can cause side effects, although not everybody gets them.
➢ If any of the above symptoms occur, the patient should immediately stop taking the medicine and contact their doctor or go to the emergency department of the nearest hospital.
The patient should not take a double dose to make up for the missed dose.
Very Rare(may occur in less than 1 in 10,000 people)
decrease in the number of certain types of white blood cells (agranulocytosis)
Unknown Frequency(cannot be estimated from the available data)
infections with bacteria or fungi that are not sensitive to the medicine
hearing disturbances - occur especially in patients receiving erythromycin in high doses and (or) in patients with liver and kidney failure; usually disappear after discontinuation of the medicine
abdominal pain, nausea, vomiting, diarrhea
transient increase in liver enzyme activity
If the patient experiences any side effects, including those not listed in this leaflet, they should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Aleje Jerozolimskie 181C; 02-222 Warsaw
Phone: +48 22 49 21 301;
Fax: +48 22 49 21 309;
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medicine.
Keep out of the sight and reach of children.
Store in a temperature below 25°C. Protect from light and moisture.
Do not use the medicine after the expiry date stated on the packaging after "EXP". The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance of the medicine is erythromycin.
One film-coated tablet contains 200 mg of erythromycin.
The excipients are:
tablet core: rice starch, sodium carboxymethyl starch (type A), gelatin, polysorbate 80, talc, magnesium stearate, potato starch
coating: polyacrylic resin (Eudragit L30-D55), triethyl citrate, talc.
White to cream-colored, round, biconvex tablets.
Packaging:16 film-coated tablets.
Tarchomińskie Zakłady Farmaceutyczne "Polfa" Spółka Akcyjna
ul. A. Fleminga 2
03-176 Warsaw
Phone number: (22) 811-18-14
In order to obtain more detailed information about this medicine, the patient should contact the marketing authorization holder.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.